Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
At Urban Wellness Group, your safety and comfort are our top priorities
You can choose a plan that best works for your lifestyle and wellness needs
61 AN OPEN-LABEL ROLLOVER STUDY FOLLOWING A RANDOMIZED TRIAL FOR CHRONIC HEPATITIS B WITH HIGH SERUM VIRAL LOAD BUT MILD ELEVATED AMINOTRANSFERASE Yao-Chun Hsu 1 , Chi-Yi Chen 2 , Cheng-Hao Tseng 3 , Chieh-Chang Chen 4 , Teng-Yu Lee* 5 , Ming-Jong Bair 6 , Jyh-Jou Chen 7 , I-Wei Chang 8 , CHi-Yang Chang 9 , Ming-Shiang Wu 10 and Jaw-Town Lin 1 , (1)E-Da Hospital, (2)Ditmanson Medical Foundation Chiayi Christian Hospital, Chia Yi, Taiwan, (3)E-Da Cancer Hospital, I-Shou University, (4)National Taiwan University Hospital, (5)Taichung Veterans General Hospital, (6)Mackay Memorial Hospital-Taitung, (7)Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan, (8)Taipei Medical Universtiy, (9)Fu-Jen Catholic University, (10)Tainan Municipal Hospital Background: This study extends the follow-up of participants who completed a randomized placebo-controlled trial evaluating the safety and efficacy of tenofovir disoproxil fumarate (TDF) in reducing the risk of histological progression in patients with chronic hepatitis B (CHB) characterized by high viral load and minimally raised serum alanine aminotransferase (ALT) levels
At 2.5 mg/mL, each 10-unit mark is 0.25 mg, and the full 100-unit syringe covers 2.5 mg
It is also approved kosher and does not contain any major allergens
US$ 27.35
US$ 20.21
US$ 28.00
US$ 28.34
